These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 1597239)

  • 21. Long-term recurrence of thyroid cancer after thyroid remnant ablation with 1.1 and 3.7 GBq radioiodine.
    Rosário PW; Purisch S; Vasconcelos FP; Padrão EL; Rezende LL; Barroso AL
    Nucl Med Commun; 2007 Jun; 28(6):507-8. PubMed ID: 17460543
    [No Abstract]   [Full Text] [Related]  

  • 22. Long-term follow-up in toxic solitary autonomous thyroid nodules treated with radioactive iodine.
    Huysmans DA; Corstens FH; Kloppenborg PW
    J Nucl Med; 1991 Jan; 32(1):27-30. PubMed ID: 1988632
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Thyroid cancer: radiation safety precautions in 131I therapy based on actual biokinetic measurements.
    Liu B; Peng W; Huang R; Tian R; Zeng Y; Kuang A
    Radiology; 2014 Oct; 273(1):211-9. PubMed ID: 24895877
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Radioiodine as an adjuvant therapy and its role in follow-up of differentiated thyroid cancer.
    Padma S; Sundaram PS
    J Cancer Res Ther; 2016; 12(3):1109-1113. PubMed ID: 28054519
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Radioiodine-131 therapy for well-differentiated thyroid cancer--a quantitative radiation dosimetric approach: outcome and validation in 85 patients.
    Maxon HR; Englaro EE; Thomas SR; Hertzberg VS; Hinnefeld JD; Chen LS; Smith H; Cummings D; Aden MD
    J Nucl Med; 1992 Jun; 33(6):1132-6. PubMed ID: 1597728
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [131 iodine: medical use. Carcinogenic and genetic effects].
    Schlumberger M; De Vathaire F
    Ann Endocrinol (Paris); 1996; 57(3):166-76. PubMed ID: 8949411
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Testicular dose and fertility in men following I(131) therapy for thyroid cancer.
    Hyer S; Vini L; O'Connell M; Pratt B; Harmer C
    Clin Endocrinol (Oxf); 2002 Jun; 56(6):755-8. PubMed ID: 12072044
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Conventional Radioiodine Therapy for Differentiated Thyroid Cancer.
    Ylli D; Van Nostrand D; Wartofsky L
    Endocrinol Metab Clin North Am; 2019 Mar; 48(1):181-197. PubMed ID: 30717901
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Relationship between estimated glomerular filtration rate and biological half-life of 131I. Retrospective analysis in patients with differentiated thyroid carcinoma.
    Vogel K; Opfermann T; Wiegand S; Biermann J; Busch M; Winkens T; Freesmeyer M
    Nuklearmedizin; 2013; 52(5):164-9. PubMed ID: 23821288
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Radiation safety in the management of patients undergoing radioactive iodine ablation therapy.
    Beck M
    Clin J Oncol Nurs; 2015 Feb; 19(1):44-6. PubMed ID: 25689648
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Radioiodine therapy for well-differentiated thyroid cancer: a quantitative dosimetric evaluation for remnant thyroid ablation after surgery.
    Samuel AM; Rajashekharrao B
    J Nucl Med; 1994 Dec; 35(12):1944-50. PubMed ID: 7989975
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Low-iodine diet in the treatment of differentiated thyroid cancer with radioactive iodine.
    Sonenberg M
    Endocrine; 2002 Mar; 17(2):141-3. PubMed ID: 12041916
    [No Abstract]   [Full Text] [Related]  

  • 33. [Dosimetric measurements and early complications in patients with differentiated thyroid carcinomas treated with radioactive iodine].
    Malesević M; Stefanović L; Adzić O; Mihoci Z; Elez D
    Med Pregl; 1992; 45(11-12):427-31. PubMed ID: 1344442
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Bone marrow dosimetry and safety of high 131I activities given after recombinant human thyroid-stimulating hormone to treat metastatic differentiated thyroid cancer.
    de Keizer B; Hoekstra A; Konijnenberg MW; de Vos F; Lambert B; van Rijk PP; Lips CJ; de Klerk JM
    J Nucl Med; 2004 Sep; 45(9):1549-54. PubMed ID: 15347723
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Low iodine diet in I-131 ablation of thyroid remnants.
    Maxon HR; Thomas SR; Boehringer A; Drilling J; Sperling MI; Sparks JC; Chen IW
    Clin Nucl Med; 1983 Mar; 8(3):123-6. PubMed ID: 6851357
    [TBL] [Abstract][Full Text] [Related]  

  • 36. TERT Promoter Mutation Predicts Radioiodine-Refractory Character in Distant Metastatic Differentiated Thyroid Cancer.
    Yang X; Li J; Li X; Liang Z; Gao W; Liang J; Cheng S; Lin Y
    J Nucl Med; 2017 Feb; 58(2):258-265. PubMed ID: 27493271
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Clinical outcomes of low-dose and high-dose postoperative radioiodine therapy in patients with intermediate-risk differentiated thyroid cancer.
    Jeong JH; Kong EJ; Jeong SY; Lee SW; Cho IH; Ah Chun K; Lee J; Ahn BC
    Nucl Med Commun; 2017 Mar; 38(3):228-233. PubMed ID: 27984538
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Juvenile differentiated thyroid carcinoma and the role of radioiodine in its treatment: a qualitative review.
    Jarzab B; Handkiewicz-Junak D; Wloch J
    Endocr Relat Cancer; 2005 Dec; 12(4):773-803. PubMed ID: 16322322
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Stunning effects in radioiodine therapy of thyroid carcinoma: existence, clinical effects and ways out].
    Koch W; Knesewitsch P; Tatsch K; Hahn K
    Nuklearmedizin; 2003 Feb; 42(1):10-4. PubMed ID: 12601448
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Stunning after tracer dosimetry.
    Diehl M; Grünwald F
    J Nucl Med; 2001 Jul; 42(7):1129. PubMed ID: 11438639
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.